Drugs and Diagnostics for Hematological Disorders: Global Markets

Published - Sep 2016| Analyst - Usha Nagavarapu| Code - PHM116B
Drugs and Diagnostics for Hematological Disorders: Global Markets
Single User License: $2750 Member Price: FREE

Report Highlights

The global market for hematology drugs and diagnostics is expected to grow from nearly $86.5 billion in 2015 to $124.3 billion in 2020 at a compound annual growth rate of 7.5% from 2015-2020.

Report Includes

  • An overview of the global market for drugs and diagnostics for hematological disorders.
  • Analyses of global market trends, with data from2015, and projections of CAGRs through 2020.
  • A breakdown of the market by hematological diseases, hematological cancers, and hematological diagnostics.
  • A review of blood cancers, such as various types of leukemia, lymphoma, and myeloma, and their therapies.
  • Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
  • Delineation of drugs approved by the FDA for hematological disorders.
  • Profiles of key companies in the industry.

SCOPE OF THE STUDY

The scope of this study covers instruments, reagents, testing, screening technology and the therapeutics markets for hematological disorders, including hemophilia and blood cancers. The report also discusses the regulatory environment, current technologies, new technologies, hematological disorders and cancer incidence, market projections and market share, along with latest trends, and clinical and new developments.

ANALYST’S CREDENTIALS

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including IND enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early startups to fulfill operational obligations while minimizing overall operational cost and burden.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Mar-2013| Analyst - Usha Nagavarapu| Code - PHM116A

Report Highlights

The total global market for hematological disorder drugs and diagnostics in 2012 was estimated at nearly $72.9 billion. By 2017, the market is expected to reach $99.1 billion, growing at a compound annual growth rate (CAGR) of 6.4% between 2012 and 2017.

Report Includes

  • An overview of the global market for drugs and diagnostics for hematological disorders.
  • Analyses of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017.
  • A breakdown of the market by hematological diseases, hematological cancers, and hematological diagnostics.
  • A review of blood cancers, such as various types of leukemia, lymphoma, and myeloma, and their therapies.
  • Delineation of drugs approved by the FDA for hematological disorders.
  • Comprehensive profiles of key companies in the industry.

CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report